Key result
Following LVAD implantation, 36.2% of patients experienced gastrointestinal bleeding, with endoscopy successfully achieving hemostasis in 96.2% of therapeutic procedures.
Why the study?
Gastrointestinal bleeding is a common complication after LVAD implantation, prompting the need to report management and outcomes in a large cohort.
What are the outcomes and safety of endoscopic management for gastrointestinal bleeding in patients with left ventricular assist devices?
Cohort (n=345)
No
What are the outcomes and safety of endoscopic management for gastrointestinal bleeding in patients with left ventricular assist devices?
Endoscopy is safe and effective for managing gastrointestinal bleeding in LVAD patients, achieving high therapeutic success with low procedure-related adverse events.
Endoscopy may support GI bleeding management in LVAD patients; leaves open need for randomized trials to guide practice.
Background and study aims Left ventricular assist device (LVAD) placement is a therapeutic modality for patients with end-stage heart failure. Gastrointestinal bleeding is a common complication following LVAD implantation. The aim of this study was to report our experience in management and outcomes of gastrointestinal bleeding in a large cohort of patients with LVADs. Patients and methods We performed a retrospective review of all patients who underwent LVAD implantation at the University of Rochester Medical Center from January 2008 to June 2017. Data were collected on patient characteristics, clinical aspects of gastrointestinal bleeding events, and procedural interventions. A Cox proportional hazard model was utilized to identify potential risk factors for a gastrointestinal bleeding event. Results During the study period, 345 patients underwent LVAD implantation. Of these, 125 patients (36.2 %) experienced 297 gastrointestinal bleeding events resulting in 533 endoscopic procedures. The diagnostic yield of endoscopy in determining a bleeding source was 49.5 %. If required, therapeutic interventions were successful in achieving homeostasis in 96.2 % of procedures. Our 30-day overall post-procedure adverse event (AE) rate was 6.6 %. Procedure-related (bleeding, infection, and perforation) AEs were very minimal (2.8 %). A Cox proportional hazard model indicated that older age at implant, female sex, African-American race, diabetes mellitus, and pulmonary hypertension were statistically significant predictors of a gastrointestinal bleeding event following LVAD implantation. Conclusions LVAD patients have a high risk of gastrointestinal bleeding. Endoscopy was able to safely locate a bleeding lesion in approximately half of our patients and was successful in treating bleeding lesions in a majority of the cases.
No takes yet. Share an insight, caveat, or question.
Taylor et al. (2020) conducted a cohort in end-stage heart failure (n=345). LVAD implantation was evaluated on gastrointestinal bleeding events. Following LVAD implantation, 36.2% of patients experienced gastrointestinal bleeding, with endoscopy successfully achieving hemostasis in 96.2% of therapeutic procedures.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: